Carbon Ion Radiotherapy: An Evidence-Based Review and Summary Recommendations of Clinical Outcomes for Skull-Base Chordomas and Chondrosarcomas

Author:

Holtzman Adam L.1ORCID,Seidensaal Katharina2,Iannalfi Alberto3ORCID,Kim Kyung Hwan4ORCID,Koto Masashi5ORCID,Yang Wan-Chin6,Shiau Cheng-Ying6,Mahajan Anita7,Ahmed Safia K.8,Trifiletti Daniel M.1,Peterson Jennifer L.1,Koffler Daniel M.1ORCID,Vallow Laura A.1,Hoppe Bradford S.1,Rutenberg Michael S.1

Affiliation:

1. Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224, USA

2. Department of Radiation Oncology, University Hospital Heidelberg, 69120 Heidelberg, Germany

3. Radiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), 27100 Pavia, Italy

4. Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea

5. QST Hospital, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan

6. Department of Heavy Particles & Radiation Oncology, Taipei Veterans General Hospital, Taipei City 11217, Taiwan

7. Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA

8. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA

Abstract

Skull-base chordoma and chondrosarcoma are rare radioresistant tumors treated with surgical resection and/or radiotherapy. Because of the established dosimetric and biological benefits of heavy particle therapy, we performed a systematic and evidence-based review of the clinical outcomes of patients with skull-base chordoma and chondrosarcoma treated with carbon ion radiotherapy (CIRT). A literature review was performed using a MEDLINE search of all articles to date. We identified 227 studies as appropriate for review, and 24 were ultimately included. The published data illustrate that CIRT provides benchmark disease control outcomes for skull-base chordoma and chondrosarcoma, respectively, with acceptable toxicity. CIRT is an advanced treatment technique that may provide not only dosimetric benefits over conventional photon therapy but also biologic intensification to overcome mechanisms of radioresistance. Ongoing research is needed to define the magnitude of benefit, patient selection, and cost-effectiveness of CIRT compared to other forms of radiotherapy.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3